Research Analysts’ Recent Ratings Changes for Opus Genetics (IRD)

Several brokerages have updated their recommendations and price targets on shares of Opus Genetics (NASDAQ: IRD) in the last few weeks:

• 3/16/2026 – Opus Genetics is now covered by Oppenheimer Holdings, Inc.. They set an “outperform” rating and a $10.00 price target on the stock.
• 3/12/2026 – Opus Genetics had its price target raised by Chardan Capital from $9.00 to $11.00. They now have a “buy” rating on the stock.
• 3/12/2026 – Opus Genetics had its price target raised by Wedbush from $8.00 to $10.00. They now have an “outperform” rating on the stock.
• 3/11/2026 – Opus Genetics was given a new $9.00 price target by Craig Hallum. They now have a “buy” rating on the stock.
• 3/2/2026 – Opus Genetics had its price target raised by BTIG Research from $7.00 to $12.00. They now have a “buy” rating on the stock.
• 3/1/2026 – Opus Genetics was upgraded by Wall Street Zen from “sell” to “hold”.
• 2/21/2026 – Opus Genetics was downgraded by Wall Street Zen from “hold” to “sell”.
• 2/12/2026 – Opus Genetics was upgraded by Lifesci Capital to “strong-buy”.
• 1/28/2026 – Opus Genetics had its “buy” rating reaffirmed by BTIG Research. They now have a $7.00 price target on the stock.
• 1/22/2026 – Opus Genetics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 1/20/2026 – Opus Genetics is now covered by BTIG Research. They set a “buy” rating and a $7.00 price target on the stock.
• 1/20/2026 – Opus Genetics is now covered by BTIG Research. They set a “buy” rating and a $7.00 price target on the stock.

Insider Activity

In other news, CEO George Magrath sold 24,438 shares of the stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $5.21, for a total value of $127,321.98. Following the completion of the sale, the chief executive officer directly owned 1,750,855 shares of the company’s stock, valued at $9,121,954.55. This represents a 1.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Cam Gallagher bought 83,000 shares of the company’s stock in a transaction dated Monday, December 29th. The stock was bought at an average price of $1.97 per share, for a total transaction of $163,510.00. Following the acquisition, the director directly owned 83,000 shares of the company’s stock, valued at approximately $163,510. This represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last ninety days, insiders sold 34,692 shares of company stock worth $180,672. 6.60% of the stock is owned by insiders.

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.